Zetiq's developed a cervical cancer biomarker.
Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) portfolio company Zetiq Technologies Ltd. reports that its biomarker for the detection of cervical cancer is compliant with European CE Standard. The certification means that the company can market the product in all countries that use European regulatory standards under the CE Mark.
Zetiq is led by CEO Dr. Adi Elkeles. The company's technology allows the differential detection of cancer cells.
Published by Globes [online], Israel business news - www.globes-online.com - on July 25, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010